Global Lupus Nephritis Market

Global Lupus Nephritis Market Size Insights Forecasts to 2035

• The Global Lupus Nephritis Market Size Was Estimated at USD 1.94 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.27 % from 2025 to 2035
• The Worldwide Lupus Nephritis Market Size is Expected to Reach USD 4.65 Billion by 2035
• North America is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Lupus Nephritis Market Size Was Worth Around USD 1.94 Billion In 2024 And Is Predicted To Grow To Around USD 4.65 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 8.27 % From 2025 To 2035. The application of AI-powered diagnostics could enhance early diagnosis of lupus nephritis, making treatment easier and faster, and biosimilars for biologics in autoimmune diseases may affect pricing dynamics as they enter the market. In addition, the increasing use of biosimilarsfor biologics in autoimmune diseases will ensure that the cost of treatment is positively affected by pricing dynamics.

 

Market Overview

The lupus nephritis market is the global healthcare industry segment that deals with the diagnosis, treatment, and management of lupus nephritis, which is a serious complication of the kidneys caused by systemic lupus erythematosus (SLE). This market includes pharmacologic therapies such as immunosuppressants, corticosteroids, biologics, and monoclonal antibodies, as well as supportive care and diagnostic products. It caters to hospitals, speciality clinics, research institutions, and home care settings, thanks to the increasing incidence of SLE, advances in medical technology, and awareness campaigns. The market is also influenced by current clinical trials, pipeline products, and government investments to enhance patient outcomes. In general, the lupus nephritis market is very important in meeting unmet medical needs, decreasing the burden of the disease, and encouraging innovation in the area of autoimmune and kidney diseases.

 

Congress moved to restore $10 million in funding for lupus research through the Department of Defence’s Lupus Research Program, reversing cuts made last year. This funding is part of the newly introduced federal spending bill and represents a major advocacy win for the lupus community.

 

Report Coverage

This research report categorises the lupus nephritis market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the lupus nephritis market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the lupus nephritis market.     

 

Driving Factors  

The market for lupus nephritis treatment is growing at a fast pace due to the availability of effective treatments and the development of new medications to simplify and expedite patient treatment. The growing prevalence of systemic lupus erythematosus (SLE), advancements in medical technology, and increased awareness campaigns by public and private bodies, thanks to government support, are also fueling the demand. The growing use of early genetic counselling, increased disposable income, lifestyle changes, and the increasing incidence of associated complications like seizures are also adding to the growth. In addition, heavy investments in research and development, along with continuous clinical trials and the introduction of innovative treatments, are opening new avenues. Moreover, high investment in changing healthcare infrastructure from key market players is gradually boosting the market expansion.

 

Restraining Factors  

However, rising challenges in research and development, and the high cost of treatment that countries will face, will slow down the growth rate of the lupus nephritis market. The regulations will further pose a challenge to the market in the forecast period.

 

Market Segmentation    

The lupus nephritis market share is classified into stage, medication, and route of administration.     

 

• The class 3 segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.        

Based on the stage, the lupus nephritis market is categorised into Class 1, Class 2, Class 3, and others. Among these, the class 3 segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Class 3 (Focal Lupus Nephritis) is a major segment of the lupus nephritis market because of its complexity and treatment challenges. The patients undergoing this treatment are often in need of immunosuppressive therapy, steroids, and biologics. This has resulted in a steady stream of revenue for this segment of the market.

• The corticosteroids segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the medication, the lupus nephritis market is divided into immunosuppressive drugs, corticosteroids and others. Among these, the corticosteroids segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Corticosteroids are the most widely used class of drugs and can immediately reduce symptoms, although the long-term use of these drugs is gradually declining as doctors and patients look for steroid-sparing regimens. Mycophenolate and cyclophosphamide, two immunosuppressants, are expected to have high demand growth in the coming years, with mycophenolate expected to lead the way because of its better safety and efficacy profile.

 

• The parenteral segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the route of administration, the lupus nephritis market is divided into oral, parenteral and others. Among these, the parenteral segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. With Non-IV formulations leading the pipeline, as they are more easily reversible and better tolerated by patients, Mycophenolate and corticosteroids head this section. In the Immunosuppressive market, parenteral formulations such as intravenous belimumab and cyclophosphamide are major growth drivers for speciality pharmacies.

 

Regional Segment Analysis of the Lupus Nephritis Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the lupus nephritis market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the lupus nephritis market over the predicted timeframe. Asia-Pacific leads the lupus nephritis market in terms of market share and market revenue and will continue to maintain its dominance in the coming forecast period. This is because of the rising awareness among the people of this region.

 

The lupus nephritis treatment market in India is growing at a fast pace because of the rising prevalence of the disease and the increasing accessibility of healthcare. The regulatory system of CDSCO is changing to make the approval process easier, but affordability is a major concern. The Japanese market is expected to grow by. The regulatory system of PMDA helps in ensuring that strict safety standards are followed, which in turn often leads to longer approval times.

 

North America is expected to grow at a rapid CAGR in the lupus nephritis market during the forecast period. North America represented a significant share of the overall market in 2024. The development of the market in this region is driven by the rising incidence of lupus nephritis. There is a presence of major players in this region with robust research and development capabilities to develop new therapies for the treatment of lupus nephritis. Such factors lead to the development of this region in the market.

 

The FDA approved Roche’s Gazyva®/Gazyvaro® (obinutuzumab) in October 2025 for the treatment of adult patients with active lupus nephritis, marking the first anti-CD20 monoclonal antibody to show complete renal response in a phase III trial.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organisations/companies involved within the lupus nephritis market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• AbbVie Inc.
• Anthera Pharmaceuticals, Inc.
• AstraZeneca plc
• Aurinia Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd. (Roche)
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• UCB S.A.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

 

• In January 2026, the Lupus Research Alliance announced the launch of Lupus Ventures, a new philanthropic venture fund dedicated to accelerating treatments and diagnostics for lupus and related autoimmune conditions. The fund will be managed by an experienced key life sciences investor.

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the lupus nephritis market based on the below-mentioned segments: 

  

Global Lupus Nephritis Market, By Stage

• Class 1
• Class 2
• Class 3
• Others

 

Global Lupus Nephritis Market, By Medication

• Immunosuppressive drugs
• Corticosteroids
• Others

 

Global Lupus Nephritis Market, By Route of Administration

• Oral
• Parenteral
• Others

 

Global Lupus Nephritis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the current size of the global lupus nephritis market?

The market was valued at USD 1.94 billion in 2024.

 

2. What is the projected market size by 2035?

It is expected to reach USD 4.65 billion by 2035.

 

3. What is the forecasted CAGR for the market?

The market is projected to grow at a CAGR of 8.27% from 2025 to 2035.

 

4. Which stage segment leads the market?

Class 3 (Focal Lupus Nephritis) held the largest share in 2024 and is expected to grow significantly.

 

5. Which medication type dominates the market?

Corticosteroids accounted for the largest share in 2024 due to their widespread use for quick symptom relief.

 

6. What is the leading route of administration?

The parenteral segment generated the highest revenue in 2024, driven by drugs like intravenous belimumab and cyclophosphamide.

 

7. Which region holds the largest market share?

Asia-Pacific is anticipated to maintain the largest share, fueled by rising awareness and disease prevalence.

 

8. Which region is expected to grow the fastest?

North America is projected to grow at the fastest CAGR, supported by strong R&D and key players.